The HDI model of HDAC inhibition in leukemic cells . HDI inhibits HDAC,... | Download Scientific Diagram
The targeted histone deacetylase inhibitor tefinostat (CHR-2845) shows selective in vitro efficacy in monocytoid-lineage leukaem
IN ACUTE MYELOID LEUKEMIA, THE USE IN INDUCTION OF STANDARD DOSE ARA-C IS ASSOCIATED WITH A BETTER QUALITY OF RESPONSE AS COMPARED TO AN INDUCTION REGIMEN. - ppt download
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
A Randomized Investigation of High-Dose Versus Standard-Dose Cytosine Arabinoside With Daunorubicin in Patients With Previously Untreated Acute Myeloid Leukemia: A Southwest Oncology Group Study - ScienceDirect
HDAC5 catalytic activity suppresses cardiomyocyte oxidative stress and NRF2 target gene expression - Journal of Biological Chemistry
Cancers | Free Full-Text | HDAC Inhibitors in Acute Myeloid Leukemia | HTML
A DNA/HDAC dual‐targeting drug CY190602 with significantly enhanced anticancer potency | EMBO Molecular Medicine
Valproic acid enhances the antileukemic effect of cytarabine by triggering cell apoptosis
Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors. - Abstract - Europe PMC
Targeting HDAC3, a new partner protein of AKT in the reversal of chemoresistance in acute myeloid leukemia via DNA damage response | Leukemia
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
RGFP966 Datasheet
Inhibition of Histone Deacetylases 1 and 6 Enhances Cytarabine-Induced Apoptosis in Pediatric Acute Myeloid Leukemia Cells
Cytarabine (Cytosine β-D-arabinofuranoside) | DNA Synthesis Inhibitor | MedChemExpress
HDAC deacethylation mechanism in leukemic cells . Overexpression of... | Download Scientific Diagram
A Randomized Comparison of Modified Intermediate-dose Ara-C versus High-dose Ara-C in Post-remission Therapy for Acute Myeloid Leukemia | Anticancer Research
Can we improve outcomes in patients with acute myelogenous leukemia? Incorporating HDAC inhibitors into front-line therapy - ScienceDirect
Marine Drugs | Free Full-Text | Marine Power on Cancer: Drugs, Lead Compounds, and Mechanisms | HTML
![PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar](https://d3i71xaburhd42.cloudfront.net/094147101525dbcb98a9d514f1a305a20a3a7f7c/3-Table1-1.png "PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar")
PDF] Sense and nonsense of high-dose cytarabine for acute myeloid leukemia. | Semantic Scholar
The combination of CHK1 inhibitor with G-CSF overrides cytarabine resistance in human acute myeloid leukemia | Nature Communications
Cancer Management Chapter 29: Acute leukemias
Histone Deacetylase Inhibitors in Multiple Myeloma | SpringerLink
